{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:20:16Z","timestamp":1787239216778,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe myeloid sarcoma (MS) that mimic gynecological tumors and provide guidelines for improving the diagnosis and treatment of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This case series study retrospectively analyzed the clinicopathological characteristics and oncological outcomes of female patients who were histologically diagnosed with MS after initially presenting with reproductive-system tumors at the Peking Union Medical College Hospital between January 2000 and March 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were eight cases in which MS mimicked cervical cancer, ovarian cancer, or hysteromyoma. Six patients had isolated MS, and the other two had acute myeloid leukemia (AML)-M2. The average age was 39.00\u2009\u00b1\u200914.26. They each sought advice from a gynecological oncologist at the initial visit, complaining of irregular bleeding (3\/8), low abdominal pain (3\/8), dysmenorrhea (1\/8), or an accidentally found mass (1\/8). CT\/MRI exams revealed that the average tumor size reached 5.65\u2009\u00b1\u20092.35\u00a0cm, with 50% of the tumors being larger than 8\u00a0cm. The final diagnoses were confirmed by biopsy (2\/8) or postoperative pathology (6\/8); the most frequent positive immunohistochemical markers were Ki-67 (60\u201390%), MPO (100%), LCA (62.5%), CD43 (62.5%), CD117 (62.5%), CD99 (50%), vimentin (37.5%), and lysozyme (25%). MLL\/AF9 gene fusions and CEBPA, JAK2, NRAS, and FLT3-TKD mutations were found in the patients. Six (75%) of the patients showed a complete response after upfront treatment using chemotherapy\u2009+\u2009surgery and experienced no recurrence during follow-up. The overall survival (OS) rate was 72.9%, and the 5-year OS rate was 72.9% (95%CI: 0.4056\u20131.000). The median OS was 26\u00a0months (range: 3\u201382).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For patients with isolated MS, treatment by chemotherapy and surgery are radical procedure, and initial treatment using chemotherapy alone should be considered for MS with synchronous intramedullary AML. Poor response to chemotherapy, short interval to leukemia occurrence, and heavy tumor burden (&gt;\u200910\u00a0cm) could indicate a poor prognosis for patients with MS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12905-023-02278-3","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T21:02:36Z","timestamp":1680037356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5683-8078","authenticated-orcid":false,"given":"Yu","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1885-8438","authenticated-orcid":false,"given":"Haoran","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengwei","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9112-1021","authenticated-orcid":false,"given":"Yang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"2278_CR1","doi-asserted-by":"publisher","first-page":"100773","DOI":"10.1016\/j.blre.2020.100773","volume":"47:","author":"RM Shallis","year":"2021","unstructured":"Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, et al. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: a tale of misnomers, controversy and the unresolved. Blood Rev. 2021;47:100773.","journal-title":"Blood Rev"},{"issue":"2","key":"2278_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/MOH.0000000000000571","volume":"27","author":"OA Shahin","year":"2020","unstructured":"Shahin OA, Ravandi F. Myeloid sarcoma. Curr Opin Hematol. 2020;27(2):88\u201394.","journal-title":"Curr Opin Hematol"},{"issue":"8","key":"2278_CR3","doi-asserted-by":"publisher","first-page":"e592","DOI":"10.1038\/bcj.2017.79","volume":"7","author":"G Goyal","year":"2017","unstructured":"Goyal G, Bartley AC, Patnaik MM, Litzow MR, Al-Kali A, Go RS. Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set. Blood Cancer J. 2017;7(8):e592.","journal-title":"Blood Cancer J"},{"issue":"6","key":"2278_CR4","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.3109\/10428194.2014.963080","volume":"56","author":"M Movassaghian","year":"2015","unstructured":"Movassaghian M, Brunner AM, Blonquist TM, Sadrzadeh H, Bhatia A, Perry AM, et al. Presentation and outcomes among patients with isolated myeloid sarcoma: a surveillance, epidemiology, and end results database analysis. Leuk Lymphoma. 2015;56(6):1698\u2013703. https:\/\/doi.org\/10.3109\/10428194.2014.963080.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2278_CR5","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.1097\/MAO.0000000000003478","volume":"43","author":"HD Zheng","year":"2022","unstructured":"Zheng HD, Abdel-Aty Y, Taylor C, Engholdt J, Robetorye RS, Hoxworth JM, et al. Myeloid sarcoma of the temporal bone: a unique cause of hearing loss, otalgia, and facial nerve weakness. Otol Neurotol. 2022;43(4):e435\u201341.","journal-title":"Otol Neurotol"},{"issue":"1","key":"2278_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1182\/blood.2021013394","volume":"139","author":"PE Young","year":"2022","unstructured":"Young PE, Medeiros LJ. Unexpected myeloid sarcoma of the tonsil in a patient without a history of hematological neoplasm. Blood. 2022;139(1):148. https:\/\/doi.org\/10.1182\/blood.2021013394.","journal-title":"Blood"},{"issue":"6","key":"2278_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/RLU.0000000000004028","volume":"47","author":"S Wu","year":"2022","unstructured":"Wu S, Lin Z, Shang Q, Pang Y, Chen H. Use of 68Ga-FAPI PET\/CT for detecting myeloid sarcoma of the breast and assessing early response to chemotherapy. Clin Nucl Med. 2022;47(6):549\u201350.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"2278_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/bjh.18038","volume":"197","author":"T Taylor","year":"2022","unstructured":"Taylor T, Byrne J, Errico G, Clark D. Very late extramedullary relapse of acute myeloid leukaemia as prostatic myeloid sarcoma occurring 24 years post-allograft. Br J Haematol. 2022;197(3):243.","journal-title":"Br J Haematol"},{"issue":"7","key":"2278_CR9","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.pathol.2021.12.291","volume":"54","author":"C Hartzell","year":"2022","unstructured":"Hartzell C, McLaughlin J, Nasibli J, Bains A. Myeloid sarcoma mimicking suprasellar meningioma in acute promyelocytic leukaemia. Pathology. 2022;54(7):955\u20137.","journal-title":"Pathology"},{"key":"2278_CR10","doi-asserted-by":"publisher","first-page":"671514","DOI":"10.3389\/fonc.2021.671514","volume":"11","author":"DY Lee","year":"2021","unstructured":"Lee DY, Baron J, Wright CM, Plastaras JP, Perl AE, Paydar I. Radiation therapy for chemotherapy refractory gingival myeloid sarcoma. Front Oncol. 2021;11:671514.","journal-title":"Front Oncol"},{"issue":"5","key":"2278_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.adaj.2021.01.017","volume":"152","author":"D Wang","year":"2021","unstructured":"Wang D, He K, Sroussi H, Treister N, Luskin M, Villa A, et al. Oral myeloid sarcoma as an uncommon manifestation of acute myeloid leukemia: a case series and review of the literature. J Am Dent Assoc. 2021;152(5):393-400.e8. https:\/\/doi.org\/10.1016\/j.adaj.2021.01.017.","journal-title":"J Am Dent Assoc"},{"issue":"9","key":"2278_CR12","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1056\/NEJMicm2001235","volume":"383","author":"TS Pasricha","year":"2020","unstructured":"Pasricha TS, Abraczinskas D. Gastrointestinal myeloid sarcoma. New Engl J Med. 2020;383(9):858.","journal-title":"New Engl J Med"},{"issue":"3","key":"2278_CR13","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.3892\/ol.2019.10652","volume":"18","author":"W Gui","year":"2019","unstructured":"Gui W, Li J, Zhang Z, Wang L, Zhao J, Ma L, et al. Primary hematological malignancy of the uterine cervix: a case report. Oncol Lett. 2019;18(3):3337\u201341. https:\/\/doi.org\/10.3892\/ol.2019.10652.","journal-title":"Oncol Lett"},{"issue":"11","key":"2278_CR14","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1002\/1097-0142(19840601)53:11<2530::AID-CNCR2820531127>3.0.CO;2-J","volume":"53","author":"NL Harris","year":"1984","unstructured":"Harris NL, Scully RE. Malignant lymphoma and granulocytic sarcoma of the uterus and vagina. a clinicopathologic analysis of 27 cases. Cancer. 1984;53(11):2530\u201345.","journal-title":"Cancer"},{"issue":"7","key":"2278_CR15","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00277-020-04065-8","volume":"99","author":"G Martino","year":"2020","unstructured":"Martino G, Zanelli M, Zizzo M, Quintini M, Ricci L, Marra A, et al. Uterine myeloid sarcoma. Ann Hematol. 2020;99(7):1671\u20132. https:\/\/doi.org\/10.1007\/s00277-020-04065-8.","journal-title":"Ann Hematol"},{"issue":"16","key":"2278_CR16","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood.2020004975","volume":"135","author":"A Marra","year":"2020","unstructured":"Marra A, Martino G. Placental myeloid sarcoma. Blood. 2020;135(16):1410. https:\/\/doi.org\/10.1182\/blood.2020004975.","journal-title":"Blood"},{"key":"2278_CR17","doi-asserted-by":"crossref","unstructured":"Nagamine M, Miyoshi H, Kawamoto K, Takeuchi M, Yamada K, Yanagida E, et al. Clinicopathological analysis of myeloid sarcoma with megakaryocytic differentiation. Pathology. 2021.2021.","DOI":"10.1016\/j.pathol.2021.08.015"},{"issue":"1","key":"2278_CR18","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1186\/s12885-019-6357-y","volume":"19","author":"HJ Meyer","year":"2019","unstructured":"Meyer HJ, P\u00f6nisch W, Schmidt SA, Wienbeck S, Braulke F, Schramm D, et al. Clinical and imaging features of myeloid sarcoma: a German multicenter study. BMC Cancer. 2019;19(1):1150.","journal-title":"BMC Cancer"},{"issue":"5","key":"2278_CR19","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.ejso.2020.10.030","volume":"47","author":"G Bogani","year":"2021","unstructured":"Bogani G, Sarpietro G, Ferrandina G, Gallotta V, Donato DI, V, Ditto A, et al. Enhanced recovery after surgery (ERAS) in gynecology oncology. Eur J Surg Oncol. 2021;47(5):952\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2020.10.030.","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"2278_CR20","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/s41375-020-01017-z","volume":"35","author":"K Lontos","year":"2021","unstructured":"Lontos K, Yabes JG, Farah RJ, Boyiadzis M. Impact of upfront chemotherapy on overall survival in isolated myeloid sarcoma. Leukemia. 2021;35(4):1193\u20136. https:\/\/doi.org\/10.1038\/s41375-020-01017-z.","journal-title":"Leukemia"},{"issue":"10","key":"2278_CR21","doi-asserted-by":"publisher","first-page":"e768","DOI":"10.1016\/j.clml.2021.06.001","volume":"21","author":"EG Nesbit","year":"2021","unstructured":"Nesbit EG, Rooney MK, Donnelly ED, Mittal BB, Sachdev S. Single fraction radiation for myeloid sarcoma is as effective as multi-fraction regimens for tumor regression and control. Clin Lymphoma Myeloma Leuk. 2021;21(10):e768\u201374. https:\/\/doi.org\/10.1016\/j.clml.2021.06.001.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"13","key":"2278_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2147\/ott.S230478","volume":"2020","author":"L Zhou","year":"2020","unstructured":"Zhou L, Zhang X, Feng S, Zhao N, Hu X, Huang L, et al. Urgent chemotherapy successfully rescues a near death patient of acute intracranial hypertension caused by intracranial myeloid sarcoma. Onco Targets Ther. 2020;2020(13):237\u201341. https:\/\/doi.org\/10.2147\/ott.S230478.","journal-title":"Onco Targets Ther"},{"key":"2278_CR23","doi-asserted-by":"publisher","unstructured":"Shallis RM, Pucar D, Perincheri S, Gore SD, Seropian SE, Podoltsev NA, et al. Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy. Ann Hematol. 2021.2021.\u00a0https:\/\/doi.org\/10.1007\/s00277-021-04702-w.","DOI":"10.1007\/s00277-021-04702-w"},{"key":"2278_CR24","doi-asserted-by":"publisher","first-page":"106583","DOI":"10.1016\/j.leukres.2021.106583","volume":"106","author":"M Ibrahim","year":"2021","unstructured":"Ibrahim M, Chen R, Vegel A, Panse K, Bhyravabhotla K, Harris K, et al. Treatment of myeloid sarcoma without bone marrow involvement with gemtuzumab ozogamicin-containing regimen. Leukemia Res. 2021;106:106583.","journal-title":"Leukemia Res"},{"issue":"3","key":"2278_CR25","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00277-020-04383-x","volume":"100","author":"WJ Yu","year":"2021","unstructured":"Yu WJ, Sun YQ, Han TT, Ye PP, Zhang XH, Xu LP, et al. Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study. Ann Hematol. 2021;100(3):799\u2013808. https:\/\/doi.org\/10.1007\/s00277-020-04383-x.","journal-title":"Ann Hematol"},{"issue":"1","key":"2278_CR26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ygyno.2021.04.029","volume":"162","author":"G Bogani","year":"2021","unstructured":"Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, et al. Uterine serous carcinoma. Gynecol Oncol. 2021;162(1):226\u201334. https:\/\/doi.org\/10.1016\/j.ygyno.2021.04.029.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2278_CR27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/bjh.17742","volume":"195","author":"KH Begna","year":"2021","unstructured":"Begna KH, Kittur J, Yui J, Gangat N, Patnaik MM, Al-Kali A, et al. De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. Br J Haematol. 2021;195(3):413\u20136. https:\/\/doi.org\/10.1111\/bjh.17742.","journal-title":"Br J Haematol"},{"issue":"14","key":"2278_CR28","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1080\/10428194.2021.1961235","volume":"62","author":"HA Abbas","year":"2021","unstructured":"Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, et al. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma. 2021;62(14):3402\u201310. https:\/\/doi.org\/10.1080\/10428194.2021.1961235.","journal-title":"Leuk Lymphoma"},{"issue":"108","key":"2278_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.humpath.2020.11.005","volume":"2021","author":"NY Greenland","year":"2021","unstructured":"Greenland NY, Van Ziffle JA, Liu YC, Qi Z, Prakash S, Wang L. Genomic analysis in myeloid sarcoma and comparison with paired acute myeloid leukemia. Hum Pathol. 2021;2021(108):76\u201383. https:\/\/doi.org\/10.1016\/j.humpath.2020.11.005.","journal-title":"Hum Pathol"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-023-02278-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T21:02:52Z","timestamp":1680037372000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-023-02278-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2278"],"URL":"https:\/\/doi.org\/10.1186\/s12905-023-02278-3","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"assertion":[{"value":"30 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Institutional Review Board of Peking Union Medical College Hospital (S-K 2058). The study obtained informed consent from participants or their legally authorized representatives. All procedures in the study involving human participants were performed in accordance with the World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Humans.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All presentations of case reports have informed consent for publication from all participants or their legally authorized representatives.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}